The combination of SDIX Genomic Antibody Technology™ and
the SDIX hybridoma development platform make for a powerful tool box from which
to produce high quality antibodies. The use of SDIX Genomic Antibody Technology allows for a Design for Purpose™ process
that is necessary to reliably produce functional antibodies for critical applications
in research, development, diagnostics, and therapeutics.
The process begins with SDIX scientists conducting a
rigorous and analytical study, including bioinformatic analysis, use of X-ray
crystal structures, and literature reviews, of the intended target. The study identifies the surface epitope or
epitopes most likely to generate the desired antibody given the intended
end-use application of that antibody.
The individual epitopes are then expressed directly in host organisms,
ensuring proper folding and post-translational modification of the protein
domain. The result is a targeted
specificity of the immune response towards the expressed epitope, which enables
the Design for Purpose quality of SDIX Genomic Antibodies.
Following validation of each polyclonal antibody in the
hands of the end user, SDIX scientists transition into the hybridoma
development stage. Using a robust and
highly optimized process, SDIX is able to create stable, clonal Hybridoma cell
lines. Furthermore, due to the upstream
use of Genomic Antibody Technology, the B Lymphocytes used as inputs are highly
enriched for cells producing antibodies targeting the epitope of interest. The result is a combined process that is
adept at creating hybridomas which produce a single, homogenous monoclonal
antibody that preserves the targeted specificity towards the desired epitope.